昂利康(002940.SZ)擬定增募資不超5.6億元 用於杭州藥物研發平台項目等
格隆匯4月21日丨昂利康(002940.SZ)披露2020年非公開發行股票預案,此次非公開發行股票募集資金總額(含發行費用)不超過5.6億元(含此數),扣除發行費用後的募集資金淨額將全部用於以下項目:4.9億元用於杭州藥物研發平台項目;7000.00萬元用於年產5噸多索茶鹼、20噸氫氧化鉀、3噸苯磺酸左旋氨氯地平、120噸哌拉西林鈉、25噸他唑巴坦鈉項目。
此次非公開發行數量按照募集資金總額除以發行價格確定,同時此次非公開發行數量不超過1250.00萬股(含本數),未超過此次發行前總股本9000.00萬股的30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.